论文部分内容阅读
目的对莫西沙星口服和注射制剂和头孢哌酮舒巴坦治疗下呼吸道感染进行成本-效果分析。方法选择就诊的下呼吸道感染患者120例,分成三个治疗组:莫西沙星口服组,莫西沙星注射组和头孢哌酮舒巴坦组,运用药物经济学方法对三个治疗组进行成本-效果分析比较。结果三个治疗组的有效率分别为90%、92.5%和90%,不良反应发生率分别为6.0%、4.0%和4.0%,差异均无统计学意义(P>0.05),但成本-效果比分别为3.3、35.7和9.9,差异有统计学意义(P<0.05)。结论口服莫西沙星治疗下呼吸道感染更具成本-效果优势,但还要综合考虑,具体情况具体分析。
OBJECTIVE: To evaluate the cost-effectiveness of oral and intravenous formulations of moxifloxacin and cefoperazone-sulbactam in the treatment of lower respiratory tract infections. Methods A total of 120 patients with lower respiratory tract infection were selected and divided into three treatment groups: moxifloxacin oral group, moxifloxacin injection group and cefoperazone sulbactam group. The costs of the three treatment groups were calculated using the method of pharmacoeconomics - Effect analysis and comparison. Results The effective rates of the three treatment groups were 90%, 92.5% and 90%, respectively, and the incidence of adverse reactions were 6.0%, 4.0% and 4.0% respectively, with no significant difference (P> 0.05) The differences were statistically significant (P <0.05) compared with 3.3, 35.7 and 9.9 respectively. Conclusion Oral moxifloxacin treatment of lower respiratory tract infections more cost-effective advantage, but also comprehensively consider the specific circumstances of the specific analysis.